Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lokelma for albuminuria reduction in diabetes with hyperkalemia
2019-000595-42Phase 4Terminated
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Mar 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hyperkalemia, diabetic glomerulosclerosis, diabetes mellitus type 1 (T1D) and 1 more comparing Lokelma with Placebo (2 arms). Primary endpoint: Reduction in urine albumin creatinine ratio. Started Mar 2019; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiadiabetic glomerulosclerosisdiabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-000595-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000595-42.